You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 10,006,091


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,006,091
Title:Method for the diagnosis, prognosis and treatment of lung cancer metastasis
Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
Inventor(s): Gomis; Roger (Barcelona, ES), Planet; Evarist (Barcelona, ES)
Assignee: Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES)
Application Number:14/405,724
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,006,091

Introduction

Patents are a cornerstone of innovation, providing inventors with exclusive rights to their inventions and incentivizing further research and development. The U.S. patent system, governed by the United States Patent and Trademark Office (USPTO), is designed to balance the protection of intellectual property with the promotion of innovation. This article delves into a comprehensive and critical analysis of the claims and the patent landscape surrounding United States Patent 10,006,091, exploring key aspects such as patentability, validity, and the broader implications within the U.S. patent system.

Understanding the U.S. Patent System

The U.S. patent system is rooted in the U.S. Constitution, which grants Congress the authority to promote the progress of science and useful arts by securing exclusive rights to inventors for limited times[1].

Patentability Requirements

For a patent to be granted, the invention must meet specific criteria:

  • Usefulness: The invention must be operable and provide some tangible benefit[1].
  • Novelty: The invention must not be fully anticipated by prior patents, publications, or other state of the art knowledge[1].
  • Nonobviousness: The invention must not have been readily within the ordinary skills of a competent artisan at the time it was made[1].
  • Subject Matter Eligibility: The invention must fall within the scope of patentable subject matter as defined by 35 U.S.C. §101[1].

The Patent Application Process

The journey to obtaining a patent involves several stages:

  • Application: The inventor submits a detailed application to the USPTO.
  • Examination: A USPTO examiner reviews the application to ensure it meets the patentability requirements. Over 85% of applications are rejected at least once, requiring the applicant to address the examiner's concerns through amendments or discussions[5].
  • Appeal: If the applicant disagrees with the examiner's rejections, they can appeal the decision[5].

Analyzing the Claims of Patent 10,006,091

To analyze the claims of Patent 10,006,091, one must consider the following:

Subject Matter Eligibility

Claims must define subject matter that is eligible for patenting under 35 U.S.C. §101. For instance, claims that are directed to abstract ideas without an inventive concept are not eligible for patenting, as seen in the case of Electric Power Group, LLC v. Alstom S.A. where claims related to monitoring and analyzing data were deemed ineligible[2].

Novelty and Nonobviousness

Each claim must be novel and nonobvious. This involves a thorough search of prior art to ensure the invention is not anticipated by existing knowledge. The USPTO examiner will evaluate the claims against the prior art to determine if they meet these criteria[1].

Usefulness

The claims must also demonstrate usefulness. This means the invention must be operable and provide a tangible benefit. The examiner will assess whether the invention serves a practical purpose and is not merely theoretical or speculative[1].

Patent Validity Challenges

Patent validity can be challenged on several grounds, including obviousness-type double patenting (ODP), which prevents a subsequent patent from being granted on the same invention or an obvious modification of an earlier granted patent[3].

The Impact of Patent Term Adjustments

Patent term adjustments (PTA) can extend the term of a patent due to delays caused by the Patent Office during prosecution. However, as seen in In re Cellect, such adjustments can lead to issues with ODP if not properly managed through terminal disclaimers. This highlights the importance of proactive management of patent applications to avoid invalidation due to ODP[3].

Advanced Patent Searching Techniques

To fully understand the landscape surrounding Patent 10,006,091, advanced patent searching techniques are essential. This includes analyzing the patent family, which involves identifying related patents and understanding how claims may have been amended or narrowed during the prosecution process. Such analysis helps in making informed decisions about licensing, challenging validity, and allocating resources for R&D initiatives[4].

Equity in Innovation

The patent system aims to promote equity in innovation by ensuring that all inventors have equal opportunities to protect their inventions. However, issues such as poor patent quality and the ease of challenging patent validity can affect this balance. The debate over making it easier to challenge patent validity post-grant highlights the ongoing efforts to ensure the system remains fair and effective[1].

Current Legislative and Judicial Developments

Recent legislative and judicial developments continue to shape the patent landscape. For example, the Leahy-Smith America Invents Act (AIA) introduced significant changes to the patent system, including the transition to a first-to-file system and the creation of new post-grant review procedures. Judicial decisions, such as those from the Federal Circuit, provide crucial guidance on issues like ODP and patent term adjustments[1][3].

Broader Implications

The analysis of Patent 10,006,091 is not isolated but part of a broader discussion on patent policy and innovation. The patent system's ability to protect and encourage innovation, particularly in emerging technology sectors, is crucial for economic growth. The balance between protecting intellectual property and fostering innovation is delicate and requires continuous evaluation and adjustment[1].

Key Takeaways

  • Patentability Requirements: Inventions must be useful, novel, nonobvious, and fall within patentable subject matter.
  • Patent Application Process: Involves detailed examination and potential appeals.
  • Validity Challenges: Can arise from issues like ODP and poor patent quality.
  • Advanced Searching Techniques: Essential for understanding the patent landscape and making informed decisions.
  • Equity in Innovation: Ensuring fair opportunities for all inventors is a core goal of the patent system.
  • Legislative and Judicial Developments: Continuously shape the patent landscape and guide practice.

FAQs

Q: What are the basic requirements for an invention to be patentable in the U.S.? A: An invention must be useful, novel, nonobvious, and fall within the scope of patentable subject matter as defined by 35 U.S.C. §101[1].

Q: How does the USPTO evaluate patent applications? A: The USPTO evaluates applications through a thorough examination process by a skilled scientist or engineer, ensuring the application meets the legal requirements of novelty, usefulness, and nonobviousness[5].

Q: What is obviousness-type double patenting (ODP), and how does it affect patents? A: ODP prevents a subsequent patent from being granted on the same invention or an obvious modification of an earlier granted patent. It can lead to the invalidation of patents if not managed properly through terminal disclaimers[3].

Q: Why are advanced patent searching techniques important? A: Advanced patent searching techniques help in understanding the patent family, identifying related patents, and making informed decisions about licensing, challenging validity, and allocating resources for R&D initiatives[4].

Q: How do legislative and judicial developments impact the patent landscape? A: Legislative changes, such as the Leahy-Smith America Invents Act, and judicial decisions, such as those from the Federal Circuit, provide crucial guidance and shape the practices and policies within the patent system[1][3].

Sources

  1. Congressional Research Service. Patents and Innovation Policy. August 2022.
  2. United States Court of Appeals for the Federal Circuit. Electric Power Group, LLC v. Alstom S.A.. July 2016.
  3. Mintz. Federal Circuit Puts the Onus on Patent Owners to Disclaim Patent. September 2023.
  4. CAS.org. Advanced patent searching techniques. July 2023.
  5. PhRMA. IP Explained: How does the U.S. patent process work?. June 2021.

More… ↓

⤷  Subscribe

Details for Patent 10,006,091

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. PROLIA denosumab Injection 125320 June 01, 2010 ⤷  Subscribe 2039-02-26
Amgen Inc. XGEVA denosumab Injection 125320 November 18, 2010 ⤷  Subscribe 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.